- Home
- COE vs ALVR Comparison
COE vs ALVR Comparison
Compare COE & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- ALVR
- Stock Information
- Founded
- COE 2011
- ALVR 2013
- Country
- COE Singapore
- ALVR United States
- Employees
- COE N/A
- ALVR N/A
- Industry
- COE Other Consumer Services
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COE Real Estate
- ALVR Health Care
- Exchange
- COE Nasdaq
- ALVR Nasdaq
- Market Cap
- COE 91.5M
- ALVR 87.7M
- IPO Year
- COE 2016
- ALVR 2020
- Fundamental
- Price
- COE $14.20
- ALVR $0.57
- Analyst Decision
- COE
- ALVR Sell
- Analyst Count
- COE 0
- ALVR 5
- Target Price
- COE N/A
- ALVR $1.00
- AVG Volume (30 Days)
- COE 5.1K
- ALVR 545.6K
- Earning Date
- COE 12-16-2024
- ALVR 11-12-2024
- Dividend Yield
- COE N/A
- ALVR N/A
- EPS Growth
- COE N/A
- ALVR N/A
- EPS
- COE N/A
- ALVR N/A
- Revenue
- COE $35,705,000.00
- ALVR N/A
- Revenue This Year
- COE N/A
- ALVR N/A
- Revenue Next Year
- COE N/A
- ALVR N/A
- P/E Ratio
- COE N/A
- ALVR N/A
- Revenue Growth
- COE 66.41
- ALVR N/A
- 52 Week Low
- COE $6.00
- ALVR $0.53
- 52 Week High
- COE $19.75
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- COE 41.35
- ALVR 36.81
- Support Level
- COE $14.01
- ALVR $0.53
- Resistance Level
- COE $15.00
- ALVR $1.05
- Average True Range (ATR)
- COE 0.56
- ALVR 0.11
- MACD
- COE -0.13
- ALVR -0.04
- Stochastic Oscillator
- COE 8.88
- ALVR 7.50
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.